LinkedIn image ad examples

Attending SLEEP 2026? Join us at Booth #315 to get exclusive access to the tools, technology, and clinical insights behind WatchPAT® 400.

Managing a sleep program shouldn't be complicated. Join the ZOLL Itamar team at SLEEP 2026 to explore scalable diagnostic solutions.

Public health agencies need a secure, modern platform. IronBridge delivers real-time interoperability built for today’s data challenges.

Simplify data exchange across labs, registries, and public health agencies. IronBridge automates reporting, translation, and routing—all in one secure cloud.

Discover how Kaiser Permanente Plus™ offers access to high-quality care, including the flexibility to choose out-of-network providers.

Medicare’s Annual Notice of Change (ANOC) letters are arriving, and this year, they carry some important shifts beneficiaries can’t afford to overlook. I recently shared insights with Investopedia reporter Jeanine Skowronski about what these changes mean for seniors and the industry at large. A few highlights: ● ANOCs may bring higher out-of-pocket costs, slimmer supplemental benefits, and revised drug formularies, requiring beneficiaries to pay closer attention than ever. ● Many ANOCs are designed to look like marketing materials — but they serve as important informational documents that outline changes in coverage, costs, and service areas for the upcoming plan year. This confusion can leave patients unprepared if they go unread. Before exploring other coverage options, it’s critical for beneficiaries to compare 2025 benefits against what their plan will offer in 2026. Read the full article here: https://lnkd.in/en6jiZnJ #Medicare #HealthPolicy #PatientAdvocacy

We’re proud to announce that Kaiser Permanente was rated the nation’s top brand for value in Forbes' America’s Best Brands for Value survey. We’re the only health care organization to make the list. https://k-p.li/3WESqxE

My why behind iTAV Software & Services. My mom has never been diagnosed with dementia but she has extreme memory loss. If it weren’t for my father, she would struggle mightily to navigate the complexities of Medicare. When I contemplated my next career move, making a difference in the lives of people like my mom was the most important part of this founder journey. Having been in corporate America for three plus decades and in the C-Suite for nearly fifteen years, admittedly in some rooms people were just statistics or numbers. I wanted to be the healthcare executive and the founder to give names and faces to under-represented populations like the “front line employees” in health plans that serve “people like my mom”. Meet my mom, Willie Mae Collier, a Medicare beneficiary. #iTAV #PeopleFirstTechCo #ProfitPurposeCoexist #AEP2026

Why sell, stock, and service four separate devices, when one Medicare-reimbursed chair pays more than all of them combined? Fewer SKUs. Faster placements. One caregiver. One workflow. Ongoing billing.

Most DMEs bill ~$89/month for this placement. Others bill ~$800/month for the exact same patient scenario. Same room. Same need. Same Medicare system. The difference isn’t volume — it’s what you place.

Hydrix has been selected by SynCardia Systems, a wholly owned subsidiary of Picard Medical, Inc (NYSE: PME), to commence development collaboration on the Emperor, SynCardia’s next-generation fully implantable Total Artificial Heart (TAH). Hydrix will collaborate with SynCardia, which will draw on decades of real-world patient experience with artificial hearts, to tackle some of the most demanding challenges in cardiac care. As a fully implantable TAH, Emperor is intended to eliminate the use of an external driver, offering greater convenience and increased patient mobility. This is exactly the kind of challenge where Hydrix will build on more than 15 years supporting global artificial heart and related circulatory support device development. The Hydrix team is thrilled at the opportunity to apply deep, multi-discipline engineering capability to safety-critical cardiac technologies and to work closely with teams such as SynCardia operating at the frontier of highly regulated, life-saving medical technologies. Patrick N.J. Schnegelsberg, CEO of SynCardia Systems, said: “Hydrix’s expertise and demonstrated track record in advancing complex cardiovascular technologies will support our shared objective of developing solutions for patients with advanced heart failure.” The development collaboration reflects Picard Medical’s focus on partnering with world-class engineering organizations capable of supporting long-term, high-value development programs for mission-critical, life-sustaining technologies. 🔗 SynCardia announcement: https://lnkd.in/g6NFQVSM 🔗 Hydrix market release: https://lnkd.in/guqbBJ6C #MedTech #MedicalDevices #DigitalHealth #HealthcareInnovation #HealthTech #Cardiology #HeartFailure #ArtificialHeart #MechanicalCirculatorySupport #CardiacCare

In inverno, la luce naturale diminuisce e le luci artificiali diventano protagoniste: pioggia, fari, strade bagnate e luminarie creano riflessi continui che possono affaticare la vista. Le lenti da vista con antiriflesso Meiryo di HOYA offrono una visione nitida e confortevole anche anche quando la città brilla più del solito. 🔎 Scopri Meiryo nel Centro Ottico HOYA Center più vicino a te. #Hoya #LentiAntiriflesso

Se ti capita di allontanare il telefono per leggere un messaggio o di strizzare gli occhi davanti a un libro, non sei solo: è un segnale tipico della presbiopia, una condizione che interessa oltre 1,8 miliardi di persone nel mondo. Con l’età, il cristallino perde elasticità e mettere a fuoco da vicino diventa più difficile, soprattutto dopo ore davanti agli schermi o in ambienti con poca luce. Le lenti progressive Hoyalux iD MySelf offrono una visione chiara e naturale a ogni distanza, eliminando la necessità di cambiare occhiali e offrendo il massimo comfort visivo. 🔎 Scopri il Centro Ottico HOYA Center più vicino a te!

Clear sections to whole organs in minutes with UbiClear. Safe, easy, and compatible with immunostaining on confocal & light-sheet microscopes.

Insomnia disorder is still underrecognized and underfunded in many public health systems despite its high burden and links to other serious health conditions. A newly published “wake-up call” position paper in Sleep Medicine – authored by sleep and mental health experts from Europe and Canada – calls for urgent policy action: ✅ Recognizing chronic insomnia as a disorder to enhance support for patients ✅ Implementing individualized clinical care and widespread sleep health programs at the community level ✅ Harmonizing access to treatments through integration of insomnia disorder in public health agendas This independent position paper is a critical reminder of the significant impact insomnia disorder has on individuals and society. At Idorsia, we support this wake-up call and are committed to elevating awareness of insomnia disorder and improving the lives of people living with the condition.

Many labs explore automation later than planned because it feels expensive or complex. It doesn’t have to be. We’re offering one lab the opportunity to evolve with confidence: – A tailored Lab Evolution Consultation – 50% off an ASSIST PLUS pipetting robot Take the first step now toward effortless lab automation.

New webinar alert! Join us for a 30-minute live webinar on Thursday 19th March to discover how Hypha uniquely integrates LC-MS/MS-based MetID with scalable metabolite synthesis and definitive structure confirmation by NMR spectroscopy. This enables metabolites to be made, identified and tested early on. Register for one of 2 time options at https://lnkd.in/eyPdxi-k

Still choosing between manual control and electronic speed? With SWITCH, you don’t have to. ✔ Familiar manual feel with precise control ✔ Faster aliquoting in repeat dispense mode - hassle-free setup ✔ Ergonomic design, to reduce hand strain and RSI risk (based on research in partnership with the Zurich University of Applied Sciences) See how SWITCH fits into your workflow.

Here we highlight a major metabolite with a prolonged plasma half-life first detected in the human mass balance study. This open access paper by scientists at Merck KGaA describes generation, identification and evaluation of a major hydroxylated metabolite (M493) of xevinapant in which Hypha Discovery later generated the reference standard by microbial biotransformation. Although M493 was just under the 10% cut off in the human mass balance study, its longer half life in plasma warranted closer scrutiny of the metabolite. Interestingly the metabolite was not detected during in vitro profiling before the human mass balance study, likely due to its MS behaviour and in source water loss. Switching polarity was key to detection of the intact molecule. However fragment ions were not diagnostic and NMR was needed for full structural assignment. Read more at https://lnkd.in/evpys64U

AI won’t fix broken metadata. In pharma marketing, we invest in platforms, personalization engines, and analytics. But when tagging and taxonomy are inconsistent, campaigns stall, attribution blurs and teams fall back on manual fixes. That’s not a technology problem. It’s an execution gap. Learn why tagging and taxonomy must be treated as a strategic capability, with governance, ownership and operational discipline.

Consent must not be an afterthought. As privacy and personalization expectations grow, fragmented consent processes are holding life sciences organizations back. Discover how you can turn consent from a compliance checkbox into a strategic advantage powered by strong operations, centralized governance, and smart automation.

Inspira enters the quantum computing sector, targeting a critical connectivity bottleneck with its newly acquired AME platform. The Company is targeting a new 3D connectivity architecture for use in dilution cryostats. Read more >> https://lnkd.in/dE3PCVUc

Inspira begins an AME technology implementation process with a customer that is one of the world’s 10 largest U.S.-based companies, reinforcing recurring revenue-generating activity and supporting its expansion into advanced technology markets. Read more >> https://lnkd.in/d5knGcEQ

☁Thinking about moving your digital pathology infrastructure to the cloud? A well-designed cloud deployment doesn’t just reduce on-prem IT burden, it can improve performance, scalability, collaboration, and data accessibility across your organization. Our Cloud Services team works with labs to design, deploy, and manage cloud environments of our industry leading HALO platforms. Read our introductory blog post to learn what a HALO cloud deployment can look like for your organization: